PDF(Pubmed)
Abstract：
UNASSIGNED: Yokukansan is a Japanese herbal medicine used in psychiatry to treat behavioral and psychological symptoms of dementia and other psychiatric symptoms. However, the glycyrrhizic acid included in this medicine can cause pseudoaldosteronism and hypokalemia. We aimed to identify the risk factors for hypokalemia due to yokukansan.
UNASSIGNED: A retrospective cohort study was conducted on patients previously treated with yokukansan. The risk factors were determined by comparing the hypokalemia group with the non-hypokalemia group for each parameter.
UNASSIGNED: This study included 304 patients who received yokukansan treatment between April 2009 and March 2019. We found that 17.4% (n = 53) of the patients experienced yokukansan-induced hypokalemia. Risk factors detected as significantly different between patients with and without yokukansan-associated hypokalemia were low serum potassium concentration before yokukansan administration, dose 7.5 g /day or more, and dementia. Hypokalemia occurred earlier in patients with low albumin, low potassium, and dementia.
UNASSIGNED: It is necessary to pay attention to hypokalemia onset when administering yokukansan at 7.5 g or more to patients with low potassium levels and dementia. Our findings suggest that potassium levels must be checked early after yokukansan administration, especially in patients with low albumin, low potassium, and dementia.
UNASSIGNED: A retrospective cohort study was conducted on patients previously treated with yokukansan. The risk factors were determined by comparing the hypokalemia group with the non-hypokalemia group for each parameter.
UNASSIGNED: This study included 304 patients who received yokukansan treatment between April 2009 and March 2019. We found that 17.4% (n = 53) of the patients experienced yokukansan-induced hypokalemia. Risk factors detected as significantly different between patients with and without yokukansan-associated hypokalemia were low serum potassium concentration before yokukansan administration, dose 7.5 g /day or more, and dementia. Hypokalemia occurred earlier in patients with low albumin, low potassium, and dementia.
UNASSIGNED: It is necessary to pay attention to hypokalemia onset when administering yokukansan at 7.5 g or more to patients with low potassium levels and dementia. Our findings suggest that potassium levels must be checked early after yokukansan administration, especially in patients with low albumin, low potassium, and dementia.
摘要：
■Yokukansan是一种用于精神病学的日本草药，用于治疗痴呆症的行为和心理症状以及其他精神症状。然而,该药物中含有的甘草酸可引起假醛固酮增多症和低钾血症。我们的目的是确定由横流引起的低钾血症的危险因素。
■对以前接受过横流散治疗的患者进行了一项回顾性队列研究。通过比较低钾血症组和非低钾血症组的每个参数来确定危险因素。
本研究纳入了2009年4月至2019年3月期间接受横流治疗的304例患者。我们发现，17.4％（n=53）的患者经历了横血药诱导的低钾血症。在有和没有横流散相关低钾血症的患者之间检测到的显著不同的危险因素是横流散给药前血清钾浓度低，剂量7.5克/天或更多，和痴呆症。低白蛋白患者低钾血症发生较早，低钾,和痴呆症。
■当向低钾水平和痴呆的患者施用7.5g或更多的横流素时，有必要注意低钾血症的发作。我们的研究结果表明，钾水平必须在yokukansan给药后早期检查，尤其是低白蛋白患者，低钾,和痴呆症。
■对以前接受过横流散治疗的患者进行了一项回顾性队列研究。通过比较低钾血症组和非低钾血症组的每个参数来确定危险因素。
本研究纳入了2009年4月至2019年3月期间接受横流治疗的304例患者。我们发现，17.4％（n=53）的患者经历了横血药诱导的低钾血症。在有和没有横流散相关低钾血症的患者之间检测到的显著不同的危险因素是横流散给药前血清钾浓度低，剂量7.5克/天或更多，和痴呆症。低白蛋白患者低钾血症发生较早，低钾,和痴呆症。
■当向低钾水平和痴呆的患者施用7.5g或更多的横流素时，有必要注意低钾血症的发作。我们的研究结果表明，钾水平必须在yokukansan给药后早期检查，尤其是低白蛋白患者，低钾,和痴呆症。
